Cerus Corp. (CERS)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1020214 · fiscal year ends in Dec
Closing price $2.44 on 29 Oct 2026; 52-week range $1.40 to $3.28.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $490.7M
- Cash
- $18.0M
- Debt
- $65.1M
- Debt to equity
- 0.93
- Shares outstanding
- 201.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $233.8M | -$8.7M | -$15.6M | -$0.08 | $1.1M | 10-K filed 2 Mar 2026 |
| FY2024 | 31 Dec 2024 | $201.3M | -$14.2M | -$20.9M | -$0.11 | $8.5M | 10-K filed 26 Feb 2025 |
| FY2023 | 31 Dec 2023 | $186.8M | -$30.1M | -$37.5M | -$0.21 | -$47.8M | 10-K filed 5 Mar 2024 |
| FY2022 | 31 Dec 2022 | $188.3M | -$34.1M | -$42.8M | -$0.24 | -$27.6M | 10-K filed 1 Mar 2023 |
| FY2021 | 31 Dec 2021 | $159.5M | -$48.9M | -$54.4M | -$0.32 | -$34.8M | 10-K filed 22 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $57.4M | -$2.9M | -$0.01 |
| Q1 FY2026 | 31 Mar 2026 | $53.7M | -$1.6M | -$0.01 |
| Q2 FY2025 | 30 Jun 2025 | $52.4M | -$5.7M | -$0.03 |
| Q1 FY2025 | 31 Mar 2025 | $43.2M | -$7.7M | -$0.04 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Product | $206.1M | 88.2% |
| Government Contract | $27.7M | 11.8% |
Company events
The newest 8-K filings of 230 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 30 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 10 Jul 2026 | 8-K | Leadership change | 5.02 |
| 8 Jun 2026 | 8-K | Material agreement, Agreement ended, New debt | 1.01, 1.02, 2.03 |
| 3 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07 |
| 30 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 21 Apr 2026 | 8-K | Leadership change | 5.02 |
| 16 Mar 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 2 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Jan 2026 | 8-K | Leadership change | 5.02 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 5 Aug 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 620 held.
| Filed | Form | Period |
|---|---|---|
| 30 Jul 2026 | S-8 | – |
| 30 Jul 2026 | 10-Q | 30 Jun 2026 |
| 30 Jul 2026 | 8-K | 30 Jul 2026 |
| 10 Jul 2026 | 8-K | 6 Jul 2026 |
| 8 Jun 2026 | 8-K | 5 Jun 2026 |
| 3 Jun 2026 | 8-K | 2 Jun 2026 |
| 29 May 2026 | SD | – |
| 30 Apr 2026 | 10-Q | 31 Mar 2026 |
| 30 Apr 2026 | 8-K | 30 Apr 2026 |
| 22 Apr 2026 | ARS | 31 Dec 2025 |
| 22 Apr 2026 | DEFA14A | – |
| 22 Apr 2026 | DEF 14A | 22 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 17 Aug 2026 | Jensen Chrystal, Chief Legal Officer | Sale under a trading plan | 30,000 | $2.98 | $89.5K | 936,657 | 17 Aug 2026 |
| 16 Jul 2026 | Jayaraman Vivek K, Chief Executive Officer | Sale under a trading plan | 16,666 | $3.16 | $52.7K | 2,232,211 | 20 Jul 2026 |
| 30 Jun 2026 | Green Kevin Dennis, Chief Financial Officer | Sale under a trading plan | 33,676 | $2.94 | $99.1K | 1,062,188 | 2 Jul 2026 |
| 30 Jun 2026 | Jayaraman Vivek K, Chief Operating Officer | Sale under a trading plan | 42,359 | $2.94 | $124.7K | 1,694,348 | 2 Jul 2026 |
| 30 Jun 2026 | Jensen Chrystal, Chief Legal Officer | Sale under a trading plan | 24,329 | $2.94 | $71.6K | 966,657 | 2 Jul 2026 |
| 30 Jun 2026 | Greenman William Mariner, President and CEO | Sale under a trading plan | 101,919 | $2.94 | $299.9K | 5,053,036 | 2 Jul 2026 |
| 9 Jun 2026 | Bjerkholt Eric, Director | Sale outside a trading plan | 20,454 | $2.60 | $53.2K | 261,679 | 11 Jun 2026 |
| 29 May 2026 | Jayaraman Vivek K, Chief Operating Officer | Sale under a trading plan | 16,667 | $3.00 | $50.0K | 1,656,707 | 2 Jun 2026 |
| 1 May 2026 | Jayaraman Vivek K, Chief Operating Officer | Sale under a trading plan | 16,667 | $3.00 | $50.0K | 1,673,374 | 5 May 2026 |
| 12 Mar 2026 | Jayaraman Vivek K, Chief Operating Officer | Sale under a trading plan | 165,200 | $1.66 | $273.8K | 1,747,674 | 16 Mar 2026 |
| 12 Mar 2026 | Greenman William Mariner, President and CEO | Sale under a trading plan | 447,757 | $1.66 | $742.0K | 4,998,493 | 16 Mar 2026 |
| 12 Mar 2026 | Green Kevin Dennis, Chief Financial Officer | Sale under a trading plan | 127,544 | $1.66 | $211.4K | 1,040,551 | 16 Mar 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 17 Aug 2026 | CHRYSTAL NIKOLE JENSEN, Officer | 30,000 | $89.5K | 17 Aug 2026 |
| 16 Jul 2026 | VIVEK K JAYARAMAN, Officer | 16,666 | $52.7K | 16 Jul 2026 |
| 9 Jun 2026 | ERIC BJERKHOLT, Director | 20,454 | $53.2K | 9 Jun 2026 |
| 29 May 2026 | VIVEK K JAYARAMAN, Officer | 16,667 | $50.0K | 29 May 2026 |
| 1 May 2026 | VIVEK K JAYARAMAN, Officer | 16,667 | $50.0K | 1 May 2026 |
| 1 May 2026 | RICHARD J BENJAMIN, Officer | 76,209 | $214.6K | 1 May 2026 |
| 9 Mar 2026 | RICHARD J BENJAMIN, Officer | 40,426 | $76.0K | 9 Mar 2026 |
| 5 Mar 2026 | KEVIN D GREEN, Officer | 55,225 | $113.9K | 5 Mar 2026 |
| 5 Mar 2026 | RICHARD J BENJAMIN, Officer | 61,233 | $126.3K | 5 Mar 2026 |
| 24 Nov 2025 | CHRYSTAL NIKOLE JENSEN, Officer | 55,000 | $93.5K | 24 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Baker Bros. Advisors LP | 13G amended | 3.2% | 6.4M |
| 14 Aug 2026 | ARK Investment Management LLC | 13G amended | 8.95% | 17.9M |
| 13 Aug 2026 | Soleus Capital Master Fund, L.P. | 13G amended | 1.2% | 2.5M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 24 Mar 2026 | Soleus Capital Master Fund, L.P. | 13G | 5.1% | 9.8M |
| 14 Nov 2025 | Baker Bros. Advisors LP | 13G amended | 5.2% | 10.0M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 16.6M | -5.41% | 9.39 |
| 30 Sep 2026 | 17.6M | -2.3% | 8.03 |
| 15 Sep 2026 | 18.0M | +1.56% | 16.58 |
| 31 Aug 2026 | 17.7M | +2.23% | 10.02 |
| 14 Aug 2026 | 17.3M | +15.85% | 5.07 |
| 31 Jul 2026 | 15.0M | +9.29% | 5.71 |
| 15 Jul 2026 | 13.7M | +7.46% | 5.5 |
| 30 Jun 2026 | 12.7M | -35.33% | 4.14 |
Funds that hold it
From each fund's latest Form 13F.
203 funds held it at 30 Jun 2026: 105 added and 51 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 22,215,127 | $64.9M | +639,708 |
| ARK Investment Management LLC | 17,932,099 | $52.4M | -1,229,049 |
| Vanguard Capital Management LLC | 8,563,424 | $25.0M | +431,646 |
| Baker Bros. Advisors LP | 6,395,431 | $18.7M | -3,612,914 |
| D. E. Shaw & Co., Inc. | 5,485,983 | $16.0M | +1,754,832 |
| Geode Capital Management, LLC | 5,119,019 | $15.0M | +481,579 |
| State Street Corp. | 4,753,962 | $13.9M | +539,060 |
| Senvest Management, LLC | 4,614,061 | $13.5M | +500,000 |
| Acadian Asset Management LLC | 4,270,074 | $12.5M | +560,573 |
| Sumitomo Mitsui Trust Group, Inc. | 4,139,532 | $12.1M | -377,074 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B